We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the worldwide commercial launch of a new automated instrument, BD FACSDuet Premium Sample Preparation System. It prepares samples for clinical diagnostics using flow cytometry, enabling a complete workflow solution designed to improve standardization and reproducibility in cellular diagnostics.
The BD FACSDuet Premium System, which has achieved in vitro diagnostics (IVD) status in the United States and Europe, is now available to order via local sales representatives.
The latest announcement is expected to significantly strengthen BD’s foothold in the global Biosciences business, which is part of its broader Life Sciences arm.
Significance of the Launch
Per BD, flow cytometry is an essential tool for clinical diagnostics and is commonly applied in the diagnosis and management of diseases like cancer.
The BD FACSDuet Premium Sample Preparation System will likely leverage liquid-handling robotics to automate the entire sample preparation process for both IVD and user-defined tests. The system then is expected to automatically transfer samples to the physically integrated BD FACSLyric Clinical Flow Cytometry System without human interaction.
As the BD FACSDuet Premium System is integrated with the flow cytometer, it enables a workflow solution that needs fewer manual steps, resources and less user hands-on time, unlike previous solutions.
BD’s management expects to usher in greater levels of automation in clinical lab workflow with the aid of the FACSDuet Premium System along with its flagship BD FACSLyric Flow Cytometry System. Management believes that more automation will enable its customers to focus more time on analyzing and interpreting samples and impacting outcomes.
Industry Prospects
Per a report by BCC Research, the global market for flow cytometry was valued at $5.2 billion in 2022 and is expected to reach $7.6 billion in 2027 at a CAGR of 8%. Factors like technological advancements, the increasing trend toward single-cell analysis and the growing adoption of flow cytometry in clinical applications are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen BD’s business worldwide.
Notable Developments in Life Sciences Arm
Last month, BD announced the worldwide commercial launch of a new-to-world cell sorting instrument, BD FACSDiscover S8 Cell Sorter, featuring two breakthrough technologies (BD SpectralFX Technology and BD CellView Image Technology).
The same month, BD received the FDA’s 510(k) clearance for the new BD Kiestra Methicillin-resistant Staphylococcus aureus imaging application. The application uses artificial intelligence to interpret bacterial growth and release negative specimens with minimal human interaction.
Also, in May, BD announced its second-quarter fiscal 2023 results, wherein it recorded solid top-line and bottom-line results and improvements in the overall base revenues. Robust performances by both geographic regions were also seen. The BD Life Sciences segment’s Integrated Diagnostic Solutions business unit saw growth in Microbiology. The Biosciences business unit also registered continued double-digit growth in Research Reagents.
Price Performance
Shares of BD have gained 7.9% in the past year compared with the industry’s 20.1% rise and the S&P 500's 19.4% growth.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hologic, Inc. (HOLX - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average being 27.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has gained 16.5% compared with the industry’s 17.7% rise in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Merit Medical has gained 59.6% compared with the industry’s 20.1% rise over the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%.
Boston Scientific has gained 49.3% against the industry’s 20.4% decline over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the worldwide commercial launch of a new automated instrument, BD FACSDuet Premium Sample Preparation System. It prepares samples for clinical diagnostics using flow cytometry, enabling a complete workflow solution designed to improve standardization and reproducibility in cellular diagnostics.
The BD FACSDuet Premium System, which has achieved in vitro diagnostics (IVD) status in the United States and Europe, is now available to order via local sales representatives.
The latest announcement is expected to significantly strengthen BD’s foothold in the global Biosciences business, which is part of its broader Life Sciences arm.
Significance of the Launch
Per BD, flow cytometry is an essential tool for clinical diagnostics and is commonly applied in the diagnosis and management of diseases like cancer.
The BD FACSDuet Premium Sample Preparation System will likely leverage liquid-handling robotics to automate the entire sample preparation process for both IVD and user-defined tests. The system then is expected to automatically transfer samples to the physically integrated BD FACSLyric Clinical Flow Cytometry System without human interaction.
As the BD FACSDuet Premium System is integrated with the flow cytometer, it enables a workflow solution that needs fewer manual steps, resources and less user hands-on time, unlike previous solutions.
BD’s management expects to usher in greater levels of automation in clinical lab workflow with the aid of the FACSDuet Premium System along with its flagship BD FACSLyric Flow Cytometry System. Management believes that more automation will enable its customers to focus more time on analyzing and interpreting samples and impacting outcomes.
Industry Prospects
Per a report by BCC Research, the global market for flow cytometry was valued at $5.2 billion in 2022 and is expected to reach $7.6 billion in 2027 at a CAGR of 8%. Factors like technological advancements, the increasing trend toward single-cell analysis and the growing adoption of flow cytometry in clinical applications are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen BD’s business worldwide.
Notable Developments in Life Sciences Arm
Last month, BD announced the worldwide commercial launch of a new-to-world cell sorting instrument, BD FACSDiscover S8 Cell Sorter, featuring two breakthrough technologies (BD SpectralFX Technology and BD CellView Image Technology).
The same month, BD received the FDA’s 510(k) clearance for the new BD Kiestra Methicillin-resistant Staphylococcus aureus imaging application. The application uses artificial intelligence to interpret bacterial growth and release negative specimens with minimal human interaction.
Also, in May, BD announced its second-quarter fiscal 2023 results, wherein it recorded solid top-line and bottom-line results and improvements in the overall base revenues. Robust performances by both geographic regions were also seen. The BD Life Sciences segment’s Integrated Diagnostic Solutions business unit saw growth in Microbiology. The Biosciences business unit also registered continued double-digit growth in Research Reagents.
Price Performance
Shares of BD have gained 7.9% in the past year compared with the industry’s 20.1% rise and the S&P 500's 19.4% growth.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hologic, Inc. (HOLX - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average being 27.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has gained 16.5% compared with the industry’s 17.7% rise in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Merit Medical has gained 59.6% compared with the industry’s 20.1% rise over the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%.
Boston Scientific has gained 49.3% against the industry’s 20.4% decline over the past year.